Drug Profile
Research programme: tat/rev antagonists - Sangamo Therapeutics
Latest Information Update: 12 Jan 2017
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Class
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 27 Aug 2001 This programme is still in active development
- 27 Aug 2001 This programme is available for licensing (http://www.sangamo.com)